Less radiation in a more tailored manner best for uterine cancer

Less radiation, delivered in a more tailored manner, is very effective and should be preferred over longer-term conventional radiation therapy in treating one of the most virulent forms of uterine cancer, according to a University of Rochester Medical Center study published in this month’s Gynecologic Oncology.

The study evaluated cases of aggressive subtypes of endometrial cancer, called papillary serous or clear cell cancer, treated with tailored, high-dose radiation treatments conducted in four office visits over four weeks. Conventional and more extensive radiation therapy for these subtypes consists of five weeks of daily treatments. Led by Brent DuBeshter, M.D., head of the Division of Gynecologic Oncology for the Wilmot Cancer Center and the Department of Obstetrics and Gynecology at the University of Rochester Medical Center, researchers determined patients had excellent localized control of their tumors with the more tailored, less extensive form of treatment.

“The obvious benefit to patients is having the same success from treatment and better control of the disease with less radiation overall, considerably fewer treatments, and fewer side effects,” says DuBeshter, who will present the findings in October to the International Society of Gynecologic Cancer’s meeting in Edinburgh, Scotland. “The next step is to explore the impact of adding chemotherapy to radiation in treating these cancers.”

Endometrial or uterine cancer – rapid and uncontrolled growth of cells in the lining of the uterus – is the most common gynecological cancer, striking 40,000 women annually in the United States and causing about 7,000 deaths. Up to 20 percent of cases are the virulent subtype studied.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New therapeutic target overcomes ovarian cancer immunotherapy resistance